Vanguard Group Inc. Sells 77,143 Shares of Agios Pharmaceuticals, Inc. $AGIO

Vanguard Group Inc. trimmed its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 1.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,604,876 shares of the biopharmaceutical company’s stock after selling 77,143 shares during the quarter. Vanguard Group Inc. owned 9.61% of Agios Pharmaceuticals worth $224,980,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the company. The Manufacturers Life Insurance Company grew its stake in shares of Agios Pharmaceuticals by 0.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 132,083 shares of the biopharmaceutical company’s stock valued at $4,393,000 after purchasing an additional 512 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH lifted its position in Agios Pharmaceuticals by 1.2% during the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 55,284 shares of the biopharmaceutical company’s stock valued at $1,839,000 after purchasing an additional 633 shares in the last quarter. California State Teachers Retirement System grew its holdings in Agios Pharmaceuticals by 1.4% during the second quarter. California State Teachers Retirement System now owns 47,659 shares of the biopharmaceutical company’s stock valued at $1,585,000 after purchasing an additional 671 shares during the period. Russell Investments Group Ltd. increased its position in Agios Pharmaceuticals by 8.6% in the second quarter. Russell Investments Group Ltd. now owns 9,292 shares of the biopharmaceutical company’s stock worth $309,000 after buying an additional 734 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its stake in shares of Agios Pharmaceuticals by 23.4% in the second quarter. PNC Financial Services Group Inc. now owns 4,419 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 837 shares during the period.

Insiders Place Their Bets

In other news, CEO Brian Goff sold 18,703 shares of the business’s stock in a transaction dated Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total value of $506,664.27. Following the sale, the chief executive officer directly owned 136,583 shares in the company, valued at $3,700,033.47. The trade was a 12.04% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider James William Burns sold 2,932 shares of the stock in a transaction dated Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total transaction of $79,427.88. Following the completion of the transaction, the insider directly owned 31,718 shares of the company’s stock, valued at approximately $859,240.62. The trade was a 8.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 33,303 shares of company stock worth $901,977. Insiders own 4.93% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on AGIO. HC Wainwright increased their target price on shares of Agios Pharmaceuticals from $62.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, February 12th. Leerink Partners increased their price objective on shares of Agios Pharmaceuticals from $34.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday, December 26th. Royal Bank Of Canada downgraded shares of Agios Pharmaceuticals from an “outperform” rating to a “sector perform” rating and decreased their price objective for the company from $57.00 to $28.00 in a research report on Wednesday, November 19th. JPMorgan Chase & Co. upped their target price on shares of Agios Pharmaceuticals from $20.00 to $25.00 and gave the stock a “neutral” rating in a report on Tuesday, January 6th. Finally, Bank of America increased their price target on Agios Pharmaceuticals from $32.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, December 24th. Six research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Agios Pharmaceuticals has a consensus rating of “Hold” and an average price target of $39.78.

Agios Pharmaceuticals Price Performance

Shares of AGIO opened at $30.23 on Monday. The stock has a market capitalization of $1.77 billion, a price-to-earnings ratio of -4.25 and a beta of 0.89. Agios Pharmaceuticals, Inc. has a 1 year low of $22.24 and a 1 year high of $46.00. The business’s 50 day simple moving average is $27.94 and its 200-day simple moving average is $33.52.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.